Brainstorm Cell Therapeutics Secures New Financing Agreement
I'm PortAI, I can summarize articles.
Brainstorm Cell Therapeutics (BCLI) has entered a financing agreement with Vanquish Funding Group, issuing a promissory note for $182,400 and receiving $155,000 after fees. The agreement allows for potential additional financing of up to $2 million over the next year. Analysts rate BCLI stock as a Hold with a $6.60 price target, but Spark's AI Analyst considers it an Underperform due to ongoing financial challenges and skepticism about its lead treatment, NurOwn. The company's market cap is $6.93M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments